Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Mark Matza MD, MBA, RhMSUS

Mark A. Matza MD, MBA, RhMSUS

Co-Clinical Director, Rheumatology, Massachusetts General Hospital; Instructor in Medicine, Harvard Medical School, Boston, Massachusetts

Dr. Mark Matza is the Co-Clinical Director of Rheumatology at the Massachusetts General Hospital and instructor in Medicine at Harvard Medical School. He completed his fellowship in rheumatology at MGH. He has interests in musculoskeletal ultrasound and giant cell arteritis and he is an investigator in multiple clinical trials in GCA. He has a special interest in the use of ultrasound in the diagnosis of giant cell arteritis and has developed a fast-track GCA program at MGH.  

Disclosures

Dr. Matza partakes in clinical trials for PMR and GCA:

  • Sarilumab (Sanofi)
  • Tocilizumab (Genentech)
  • Mavralimumab (Kiniksa)
  • Ustekinumab (Janssen)
  • Guselkumab (Janssen)
  • Secukinumab (Novartis)

Recent Contributions to PracticeUpdate:

  1. Corticosteroids Reduce Vascular Ultrasound Sensitivity in Fast-Track Pathways for Evaluation of Giant Cell Arteritis

Recently Updated